EP08.02-025 Lazertinib as a Frontline Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer: Results from the Phase I/II Trial

Abstract

Lazertinib is an oral, potent, highly mutant-selective, and brain-penetrant third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting both EGFR activating mutations and EGFR T790M while sparing wild-type EGFR. We report the efficacy and safety of lazertinib 240 mg as a frontline treatment in EGFR mutated, advanced or metastatic non-small cell lung cancer (NSCLC) in Part C frontline cohort of a single-arm phase I/II study (ClinicalTrials.gov identifier: NCT03046992).